-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] Since the beginning of this year, the tide of new shares breaking has become more and more intense.
From the perspective of industry distribution, the pharmaceutical and biological sector has become the "hardest hit area" for new shares on the Science and Technology Innovation Board.
The number of stocks on the list reached 8, accounting for 34.
78%
.
Judging from the new price of individual stocks in the pharmaceutical and biological sector, Rendu Bio is 54.
01 yuan per share; Haichuang Pharmaceutical and Myland also remain above 35 yuan per share
.
The new price of Rendu Bio has fallen by more than 20% from the issue price; the new prices of Haichuang Pharmaceutical and Mylander have fallen by more than 10% from the issue price
.
It is reported that Rendu Bio will be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on March 30, 2022, with an issue price of 72.
65 yuan per share
.
On the day of listing, Rendu Bio fell below the issue price at the opening, and the opening price was 68.
00 yuan, a decrease of 6.
40%, and then broke through the whole day
.
Recently, Rendu Bio released its 2022 semi-annual report.
The report shows that in the first half of this year, the company achieved an operating income of 170 million yuan, a year-on-year increase of 21.
07%; the net profit attributable to shareholders of the listed company was 21.
9216 million yuan, a year-on-year decrease of 33.
64%; The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 17.
113 million yuan, a year-on-year decrease of 46.
66%; the net cash flow from operating activities was -5.
2967 million yuan, a year-on-year decrease of 140.
50%
.
According to the data, Rendu Bio’s main business is the research and development, production and sales of molecular diagnostic reagents and equipment integrated products based on the technology platform of RNA real-time fluorescence isothermal amplification (SAT), focusing on reproduction, respiration, digestion, Provide solutions for accurate diagnosis, effective prevention and control, and personalized diagnosis and treatment of pathogens in the fields of blood, food, and environmental safety
.
The total amount of funds raised by Rendu Bio is 726.
5000 million yuan.
After deducting the issuance expenses, the net amount of funds raised is 652.
7649 million yuan
.
The raised funds are planned to be used for the "Research and Development Project of Precision Diagnostic Reagents and Intelligent Equipment Industrialization" and "Marketing Network Construction Project" respectively
.
Haichuang Pharmaceutical was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on April 12, 2022.
The issue price was 42.
92 yuan per share, and the number of publicly issued shares was 24,760,000 shares, accounting for about 25.
01% of the issued share capital
.
According to the data, Haichuang Pharmaceutical focuses on the research and development of innovative drugs in major therapeutic areas such as tumors and metabolic diseases
.
As of the prospectus signing date, the company has 10 main products under development, of which 9 are new drugs independently developed and 1 is a new drug introduced through cooperation
.
The total amount of funds raised by Haichuang Pharmaceuticals is 1,062,699,200 yuan.
After deducting the issuance expenses, the net amount of funds raised is 995,113,300 yuan
.
According to the prospectus disclosed by the company on April 7, 2022, the company plans to raise funds of 2,503,958,800 yuan, which will be used for R&D and production base construction projects, innovative drug R&D projects, and development reserve funds
.
Mylander was listed on the Shanghai Stock Exchange's Science and Technology Innovation Board on August 11.
The number of publicly issued shares was 25 million shares, accounting for 25% of the total share capital after the issuance, and the issue price was 40.
29 yuan per share
.
The total amount of funds raised from its issuance was RMB 1,007.
25 million.
After deducting the issuance expenses (excluding value-added tax), the net amount of funds raised was RMB 909,758,500
.
On August 8, 2022, the prospectus released by Mylander showed that the company plans to raise funds of 573.
7794 million yuan, which will be used for the Mylander headquarters production base construction project, R&D center construction project, marketing service and informatization construction project
.
According to the data, Myland's main business is mainly engaged in the research and development, production, sales and service of related products in the field of pelvic floor and postpartum rehabilitation
.
In the first half of 2022, the company achieved an operating income of 183 million yuan, a year-on-year increase of 18.
83%, and a net profit of 46.
638 million yuan, a year-on-year decrease of 15.
62%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
From the perspective of industry distribution, the pharmaceutical and biological sector has become the "hardest hit area" for new shares on the Science and Technology Innovation Board.
The number of stocks on the list reached 8, accounting for 34.
78%
.
Judging from the new price of individual stocks in the pharmaceutical and biological sector, Rendu Bio is 54.
01 yuan per share; Haichuang Pharmaceutical and Myland also remain above 35 yuan per share
.
The new price of Rendu Bio has fallen by more than 20% from the issue price; the new prices of Haichuang Pharmaceutical and Mylander have fallen by more than 10% from the issue price
.
It is reported that Rendu Bio will be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on March 30, 2022, with an issue price of 72.
65 yuan per share
.
On the day of listing, Rendu Bio fell below the issue price at the opening, and the opening price was 68.
00 yuan, a decrease of 6.
40%, and then broke through the whole day
.
Recently, Rendu Bio released its 2022 semi-annual report.
The report shows that in the first half of this year, the company achieved an operating income of 170 million yuan, a year-on-year increase of 21.
07%; the net profit attributable to shareholders of the listed company was 21.
9216 million yuan, a year-on-year decrease of 33.
64%; The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 17.
113 million yuan, a year-on-year decrease of 46.
66%; the net cash flow from operating activities was -5.
2967 million yuan, a year-on-year decrease of 140.
50%
.
According to the data, Rendu Bio’s main business is the research and development, production and sales of molecular diagnostic reagents and equipment integrated products based on the technology platform of RNA real-time fluorescence isothermal amplification (SAT), focusing on reproduction, respiration, digestion, Provide solutions for accurate diagnosis, effective prevention and control, and personalized diagnosis and treatment of pathogens in the fields of blood, food, and environmental safety
.
The total amount of funds raised by Rendu Bio is 726.
5000 million yuan.
After deducting the issuance expenses, the net amount of funds raised is 652.
7649 million yuan
.
The raised funds are planned to be used for the "Research and Development Project of Precision Diagnostic Reagents and Intelligent Equipment Industrialization" and "Marketing Network Construction Project" respectively
.
Haichuang Pharmaceutical was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on April 12, 2022.
The issue price was 42.
92 yuan per share, and the number of publicly issued shares was 24,760,000 shares, accounting for about 25.
01% of the issued share capital
.
According to the data, Haichuang Pharmaceutical focuses on the research and development of innovative drugs in major therapeutic areas such as tumors and metabolic diseases
.
As of the prospectus signing date, the company has 10 main products under development, of which 9 are new drugs independently developed and 1 is a new drug introduced through cooperation
.
The total amount of funds raised by Haichuang Pharmaceuticals is 1,062,699,200 yuan.
After deducting the issuance expenses, the net amount of funds raised is 995,113,300 yuan
.
According to the prospectus disclosed by the company on April 7, 2022, the company plans to raise funds of 2,503,958,800 yuan, which will be used for R&D and production base construction projects, innovative drug R&D projects, and development reserve funds
.
Mylander was listed on the Shanghai Stock Exchange's Science and Technology Innovation Board on August 11.
The number of publicly issued shares was 25 million shares, accounting for 25% of the total share capital after the issuance, and the issue price was 40.
29 yuan per share
.
The total amount of funds raised from its issuance was RMB 1,007.
25 million.
After deducting the issuance expenses (excluding value-added tax), the net amount of funds raised was RMB 909,758,500
.
On August 8, 2022, the prospectus released by Mylander showed that the company plans to raise funds of 573.
7794 million yuan, which will be used for the Mylander headquarters production base construction project, R&D center construction project, marketing service and informatization construction project
.
According to the data, Myland's main business is mainly engaged in the research and development, production, sales and service of related products in the field of pelvic floor and postpartum rehabilitation
.
In the first half of 2022, the company achieved an operating income of 183 million yuan, a year-on-year increase of 18.
83%, and a net profit of 46.
638 million yuan, a year-on-year decrease of 15.
62%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
